Compare Invesco NASDAQ 100 ETF (QQQM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Invesco NASDAQ 100 ETF trades at $289.22, while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| QQQM | VRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $307.23 | $529.59 |
52-Week Low | $228.02 | $366.54 |
Market Cap | — | $122.33B |
Enterprise Value | — | $117.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $286.58 with minimal daily movement (+0.09%) amid bearish technical signals. The ETF faces headwinds from stretched tech valuations and rising AI competition, though recent Nasdaq-100 additions like SpaceX provide diversification. Technical indicators show oversold conditions with RSI at 22.39, while moving averages signal continued downward pressure.
The outlook remains cautious due to valuation concerns and sector rotation risks. However, the lower 0.15% expense ratio versus QQQ offers cost efficiency for long-term growth exposure. Key risks include AI market saturation and tech sector volatility, balanced by the fund's concentrated exposure to leading U.S. innovation companies.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
